Systematic Reviews
Copyright ©The Author(s) 2024.
World J Nephrol. Mar 25, 2024; 13(1): 90402
Published online Mar 25, 2024. doi: 10.5527/wjn.v13.i1.90402
Table 1 Characteristics of the different included studies
Ref.
Country
Patients
Design
Study period
Number of cases
Mean age (yr)
Gender M/F
Hajji et al[4], 2019TunisiaADPKDObservational descriptive1969-201656948.5297/272
Arogundade et al[5], 2018NigeriaADPKDObservational descriptive1996-20104148.6 4.623/18
Chijioke et al[6], 2010NigeriaADPKDObservational descriptive1994-20097849.8 3.652/26
Ogiator et al[7], 2021 NigeriaADPKDObservational descriptive2013-20201942.8 16.910/9
Mawufemo et al[8], 2018 TogoADPKDObservational descriptive2010-20172751.6 16.410/17
Fary Ka et al[9], 2010SenegalADPKDObservational descriptive1995-20055547.0 5.031/24
Okyere et al[10], 2021GhanaADPKDObservational descriptive2007-20188243.8 15.743/39
Laleye et al[11], 2012 BeninADPKDObservational descriptive2000-20103247.2 17/15
Abdelwahed et al[12], 2022TunisiaADPKDObservational descriptiveNA1947 1810/9
Abdelwahed et al[13], 2018TunisiaADPKDObservational descriptiveNA18458/10
Seck et al[14], 2013SenegalADPKDCase reportNA1410/1
Sahnoun et al[16], 2015 TunisiaADPKDCase reportNA1521/0
Nabhan et al[15], 2015 EgyptARPKDCase reportNA12.50/1
Total94347.9502/441
Table 2 Main clinical manifestations at presentation
Ref.
HTN (%)
Pain (%)
Hematuria (%)
Abdominal mass (%)
KFI (%)
ESKD (%)
Hajji et al[4], 2019 58.851.924.666.074.723.0
Arogundade et al[5], 2018 87.868.336.682.9100.019.5
Chijioke et al[6], 2010 26.914.1NANA32.0NA
Ogiator et al[7], 2021 42.168.431.6NA63.215.8
Mawufemo et al[8], 201877.863.022.263.063.025.9
Fary Ka et al[9], 2010 65.452.725.4NANANA
Okyere et al[10], 202150.039.02.4NA81.715.9
Laleye et al[11], 2012 59.062.046.043.072.0NA
Abdelwahed et al[12], 202257.9NA26.3NA89.5NA
Abdelwahed et al[13], 201872.2NANANANANA
Pooled prevalence [95%IC]57.4 [54.2–60.6]49.1 [45.8–52.3]24.0 [21.1–26.9]65.8 [62.2–69.4]72.1 [69.1–75.1]21.9 [18.9–24.9]
Table 3 Genetic analysis finding
Gene
Exon/Intron
Nucleotide change
Aminoacid change
Number of patients
Ref.
PKD 14c.496 C>Tp.L1662[12]
5c.696 T>Gp.C232W2[12,13]
5c.688 T>Gp.C230G1[12]
5c.690 C>Gp.C230W1[12]
7c.1522 T>Cp.C508R1[12]
8c.1702 G>Ap.A568T1[12]
9c.1745_1761dupNA1[11]
15c.4264 G>Ap.A1422T1[12]
15c.5577 T>Cp.A18591[12]
15c.4495 C>Tp.L14992[12]
15NAp.Q1651X1[11]
15NAp.W1666X1[11]
15NAc.6575_6581del1[11]
18c.7290_7291delinsCTGCANA2[11,14]
IVS22c.8161-1 G>ALikely silent4[12]
IVS42c.11712+28 C>TLikely silent1[12]
23c.8679 C>Gp.S8931[12]
23c.8715 C>Tp.V29051[12]
23c.8748 T>Cp.P29162[12]
23c.8522 A>Gp.N2841S1[12]
23NAp.Q2824X1[11]
26c.9397+1_9397+8delNA1[11]
28c.9669 G>Ap.T3223 2[12]
30c.3367G>Ap.G1123S1[15]
31c.10165 G>Cp.E3389Gln1[12]
44c.12133 A>Gp.I4045V1[12]
45c.12276 A>Gp.A40922[12,16]
PKD 21c.568 G>Ap.A190T 2[12]
1c.83 G>Cp.A28P2[12]
IVS1c.596-16 C>TLikely silent1[12]
PKHD1c.3367G>Ap.G1123S1[15]